DrugPatentWatch Database Preview
CENTANY Drug Profile
see a sample report or, see our see our flat-rate plans
When do Centany patents expire, and what generic alternatives are available?
This drug has five patent family members in five countries.
The generic ingredient in CENTANY is mupirocin. There are thirteen drug master file entries for this compound. Thirty-one suppliers are listed for this compound. Additional details are available on the mupirocin profile page.
Summary for CENTANY
| International Patents: | 5 |
| US Patents: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 2 |
| Bulk Api Vendors: | 56 |
| Clinical Trials: | 1 |
| Patent Applications: | 4,417 |
| Formulation / Manufacturing: | see details |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for CENTANY |
| DailyMed Link: | CENTANY at DailyMed |
Pharmacology for CENTANY
| Drug Class | RNA Synthetase Inhibitor Antibacterial |
| Mechanism of Action | RNA Synthetase Inhibitors |
Medical Subject Heading (MeSH) Categories for CENTANY
Synonyms for CENTANY
| (E)-(2S,3R,4R,5S)-5-((2S,3S,4S,5S)-2,3-Epoxy-5-hydroxy-4-methylhexyl)tetrahydro-3,4-dihydroxy-beta-methyl-2H-pyran-2-crotonic acid, ester with 9-hydroxynonanoic acid |
| 115074-43-6 |
| 12650-69-0 |
| 1jzs |
| 5,9-Anhydro-2,3,4,8-tetradeoxy-8-[[3-(2-hydroxy-1-methylpropyl)oxiranyl]methyl]-3-methyl-[2E,8[2S,3S(1S,2S) |
| 5,9-Anhydro-2,3,4,8-tetradeoxy-8-[[3-(2-hydroxy-1-methylpropyl)oxiranyl]methyl]-3-methyl-[2E,8[2S,3S(1S,2S)]]-L-talonon-2-enonic acid 8-carboxyoctyl ester |
| 6-Chloro-2,4-dimethoxy pyrimidine |
| 62916-63-6 |
| 8-Carboxyoctyl (E)-4-(2S,3R,4R,5S)-5-((2S,3S,4S,5S)-2,3-epoxy-5-hydroxy-4-methylhexyl)-3,4-dihydroxytetrahydro-2H-pyran-2-yl)-3-methylcrotonat |
| 80558-54-9 |
| 9-(((E)-4-((2S,3R,4R,5S)-3,4-dihydroxy-5-(((2S,3S)-3-((2S,3S)-3-hydroxybutan-2-yl)oxiran-2-yl)methyl)tetrahydro-2H-pyran-2-yl)-3-methylbut-2-enoyl)oxy)nonanoic acid |
| 9-((E)-4-((2S,3R,4R,5S)-3,4-dihydroxy-5-(((2S,3S)-3-((2S,3S)-3-hydroxybutan-2-yl)oxiran-2-yl)methyl)-tetrahydro-2H-pyran-2-yl)-3-methylbut-2-enoyloxy)nonanoic acid |
| 9-((E)-4-{(2S,3R,4R,5S)-3,4-Dihydroxy-5-[(2S,3S)-3-((1S,2S)-2-hydroxy-1-methyl-propyl)-oxiranylmethyl]-tetrahydro-pyran-2-yl}-3-methyl-but-2-enoyloxy)-nonanoic acid |
| 9-((E)-4-{(2S,3R,4R,5S)-3,4-Dihydroxy-5-[(2S,3S)-3-((1S,2S)-2-hydroxy-1-methyl-propyl)oxiranylmethyl]tetrahydro-pyran-2-yl}-3-methyl-but-2-enoyloxy)nonanoic acid calcium salt |
| 9-((E)-4-{(2S,3R,4R,5S)-3,4-Dihydroxy-5-[(2S,3S)-3-((1S,2S)-2-hydroxy-1-methyl-propyl)oxiranylmethyl]tetrahydro-pyran-2-yl}-3-methyl-but-2-enoyloxy)nonanoic acid lithium salt |
| 9-({(2E)-4-[(2S,3R,4R,5S)-3,4-dihydroxy-5-({(2S,3S)-3-[(2S,3S)-3-hydroxybutan-2-yl]oxiran-2-yl}methyl)tetrahydro-2H-pyran-2-yl]-3-methylbut-2-enoyl}oxy)nonanoic acid |
| 9-(4-((2S,3R,4R,5S)-3,4-dihydroxy-5-(((2S,3S)-3-((2S,3S)-3-hydroxybutan-2-yl)oxiran-2-yl)methyl)-tetrahydro-2H-pyran-2-yl)-3-methylbut-2-enoyloxy)nonanoic acid |
| 9-(4-{3,4-Dihydroxy-5-[3-(2-hydroxy-1-methyl-propyl)-oxiranylmethyl]-tetrahydro-pyran-2-yl}-3-methyl-but-2-enoyloxy)-nonanoic acid (Mupirocin) |
| 9-[(E)-4-[(2S,3R,4R,5S)-3,4-dihydroxy-5-[[(2S,3S)-3- [(2S,3S)-3-hydroxybutan-2-yl]oxiran-2-yl]methyl] oxan-2-yl]-3-methylbut-2-enoyl]oxynonanoic acid |
| 9-[(E)-4-[(2S,3R,4R,5S)-3,4-dihydroxy-5-[[(2S,3S)-3-[(1S,2S)-2-hydroxy-1-methyl-propyl]oxiran-2-yl]methyl]tetrahydropyran-2-yl]-3-methyl-but-2-enoyl]oxynonanoic acid |
| 9-[(E)-4-[(2S,3R,4R,5S)-3,4-dihydroxy-5-[[(2S,3S)-3-[(2S,3S)-3-hydroxybutan-2-yl]oxiran-2-yl]methyl]oxan-2-yl]-3-methylbut-2-enoyl]oxynonanoic acid |
| 9-{[(2E)-4-[(2S,3R,4R,5S)-3,4-dihydroxy-5-{[(2S,3S)-3-[(2S,3S)-3-hydroxybutan-2-yl]oxiran-2-yl]methyl}oxan-2-yl]-3-methylbut-2-enoyl]oxy}nonanoic acid |
| AB0010371 |
| AB01563109_01 |
| AC1L9JV4 |
| AKOS015994756 |
| AOB6353 |
| AS-11580 |
| Bactoderm |
| Bactroban |
| Bactroban (TN) |
| Bactroban Nasal |
| Bactroban Ointment |
| BC656995 |
| BDBM50290686 |
| BIDD:GT0320 |
| BRL 4910A |
| BRL-4910A |
| C11758 |
| C26H44O9 |
| CAS-12650-69-0 |
| CCG-213522 |
| Centany (TN) |
| CHEBI:7025 |
| CHEBI:94519 |
| CHEMBL719 |
| cid_446596 |
| CPD000471888 |
| D01076 |
| D03JSJ |
| D0GX863OA5 |
| DB00410 |
| DR003067 |
| DSSTox_CID_26438 |
| DSSTox_GSID_46438 |
| DSSTox_RID_81614 |
| DTXSID0046438 |
| HMS2234E20 |
| HMS3259L05 |
| HY-B0958 |
| KS-5137 |
| LP070857 |
| LS-177887 |
| M-8680 |
| M2955 |
| MFCD01711620 |
| MFCD11977847 |
| MINDHVHHQZYEEK-HBBNESRFSA-N |
| MLS001074711 |
| MolPort-003-666-882 |
| MRC |
| Mupirocin |
| Mupirocin (USP/INN) |
| Mupirocin [USAN:USP:INN:BAN] |
| Mupirocin calcium |
| mupirocin calcium salt |
| mupirocin lithium salt |
| Mupirocin Neo-Sensitabs |
| Mupirocin, >=92% (HPLC), powder |
| Mupirocin, 14C-Labeled |
| Mupirocin, Antibiotic for Culture Media Use Only |
| Mupirocin, Pseudomonic Acid A |
| Mupirocin, United States Pharmacopeia (USP) Reference Standard |
| Mupirocina |
| Mupirocina [Spanish] |
| Mupirocine |
| Mupirocine [French] |
| Mupirocinum |
| Mupirocinum [Latin] |
| mupricin |
| NC00620 |
| NCGC00164554-03 |
| Nonanoic acid, 9-((3-methyl-1-oxo-4-(tetrahydro-3,4-dihydroxy-5-((3-(2-hydroxy-1-methylpropyl)oxiranyl)methyl)-2H-pyran-2-yl)-2-butenyl)oxy)-, (2S-(2alpha(E),3beta,4beta,5alpha(2R*,3R*(1R*,2R*))))- |
| NSC-759182 |
| NSC759182 |
| Pharmakon1600-01505706 |
| Plasimine |
| Pseudomonic acid |
| Pseudomonic acid A |
| Pseudomonic acid A lithium salt |
| S4297 |
| SAM002589979 |
| SBI-0206892.P001 |
| SC-16672 |
| SCHEMBL1027618 |
| SCHEMBL3291 |
| SMR000471888 |
| Tox21_112183 |
| trans-Pseudomonic acid |
| Turixin |
| UNII-D0GX863OA5 |
| ZINC4102194 |
US Patents and Regulatory Information for CENTANY
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Perrigo New York | CENTANY | mupirocin | OINTMENT;TOPICAL | 050788-001 | Dec 4, 2002 | BX | RX | No | No | ➤ Try a Free Trial | ➤ Try a Free Trial | Y | ➤ Try a Free Trial | ||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
see a sample report or, see our see our flat-rate plans
Expired US Patents for CENTANY
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Perrigo New York | CENTANY | mupirocin | OINTMENT;TOPICAL | 050788-001 | Dec 4, 2002 | ➤ Try a Free Trial | ➤ Try a Free Trial |
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
see a sample report or, see our see our flat-rate plans
International Patents for CENTANY
| Country | Document Number | Estimated Expiration |
|---|---|---|
| Spain | 2165723 | ➤ Try a Free Trial |
| Canada | 2259764 | ➤ Try a Free Trial |
| European Patent Office | 0933081 | ➤ Try a Free Trial |
| Israel | 123143 | ➤ Try a Free Trial |
| Country | Document Number | Estimated Expiration |
